TOP > 外国特許検索 > MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION

MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION NEW

外国特許コード F200010047
整理番号 6205
掲載日 2020年5月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP029844
国際公開番号 WO 2020027137
国際出願日 令和元年7月30日(2019.7.30)
国際公開日 令和2年2月6日(2020.2.6)
優先権データ
  • 特願2018-143437 (2018.7.31) JP
発明の名称 (英語) MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION NEW
発明の概要(英語) The present disclosure provides: a compound represented by formula (I), for treating cerebral infarction; a medicine composition including said compound; a method for producing a medicine for treating cerebral infarction, the method comprising the use of said compound; and a method for treating cerebral infarction, the method comprising the use of said compound in preparation of a medicine for treating cerebral infarction, or the administration of said compound or medicine composition. Cerebral infarction includes, for example, lacuna infarction, atherothrombotic cerebral infarction, or cardiogenic cerebral embolism.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cerebral infarcts, in general, of the cerebral artery occlusion or stenosis caused by cerebral ischemia, brain tissue necrosis or because of lack of oxygen or nutritional necrosis and close to a disease. Is a cerebral infarction, small artery lesions in the brain due to the 'lacunar infarction', a relatively large arteries in the neck of the skull due to atherosclerosis' aiding in the cerebral infarction ', according to heart disease' cardiogenic cerebral embolism ' and the like included in the disease types. Cerebral infarcts, high mortality disease and, further, once a high possibility to leave a sequelae to develop, QOL of the patient, the medical and economic welfare is also a major challenge.
With respect to the acute phase of cerebral infarction, tissue plasminogen activator (tissue plasminogen activator: tPA or t-PA) is selected first by thrombolytic therapy. Plasminogen is, the blood vessel to be dissolved in strong clots enzyme. Brain artery by thrombus occur after the last stroke by administering tPA, clot dissolving, to restore the flow of blood treatment (thrombolytic therapy) is performed. TPA by treating the patient can be independently restored to life and 40-50% have been reported. However, the administration of tPA a long time has elapsed from the onset to the case, and can cause hemorrhage, after the onset of the patient can be used only within a period of 4.5. In addition, recently, from the onset within a patient 8 the treatment of thrombus recovery therapy by mechanical treatment of thrombus in the vessel also being. In either case the additional therapeutic improvement has been demanded strongly from the clinical field, to develop new therapies can be extremely important.
Certain of the 4-amino-naphthalene sulfonic acid derivative may have inhibitory activity, VCP(valosin-containing protein) ATPase-1-, against various diseases have been expected to have a therapeutic effect (Patent Document 1). In particular, an eye disease and leptin resistance is effective in the treatment or prophylaxis has been known (JP-2-5).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • KAKIZUKA, Akira
  • KINOSHITA, Hisanori
  • MAKI, Takakuni
  • TAKAHASHI, Ryosuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close